🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Lung Neuroendocrine Tumor

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors NCT06936735Phase 11 site📍 Shanghai Hansoh BioMedical R&D Company · Tests: HS-20108 Monotherapy A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC NCT07416695Phase 12 sites📍 Beijing📍 Shanghai Shanghai Henlius Biotech · Tests: HLX3901 Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors NCT06938880Phase 1, Phase 21 site📍 Guangzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZGGS18 for Injection, ZG005 for Injection Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites📍 San Francisco📍 Aurora📍 Atlanta Bristol-Myers Squibb · Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors NCT07006727Phase 18 sites📍 Iowa City📍 Boston📍 Royal Oak Novartis Pharmaceuticals · Tests: 225Ac-ETN029, 111In-ETN029 A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Avapritinib Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma NCT07038096Phase 1, Phase 21 site📍 Guanzhou Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Tests: ZG006, ZG005 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 A Study of IBI363 in Subjects with Advanced Solid Malignancies NCT06281678Phase 29 sites📍 San Francisco📍 Ocala📍 Plantation Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI363 Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC NCT07718243Phase 1, Phase 22 sites📍 Manchester📍 Sutton Institute of Cancer Research, United Kingdom · Tests: Bexmarilimab 1mg/kg and nivolumab 1mg/kg, Bexmarilimab 3mg/kg and nivolumab 1mg/kg, Recommended Phase II Dose Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042Phase 1, Phase 26 sites📍 Scottsdale📍 Denver📍 New Haven Simcha IL-18, Inc. · Tests: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors NCT04665739Phase 229 sites📍 Birmingham📍 Beverly Hills📍 Loma Linda National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate A Study of DXC014 in Patients With Advanced Solid Tumors. NCT07177937Phase 15 sites📍 Beijing📍 Changsha📍 Nanchang Hangzhou DAC Biotechnology Co., Ltd. · Tests: DXC014 A Study of FZ-AD005 in Patients With Advanced Solid Tumors NCT06424665Phase 13 sites📍 Changsha📍 Shanghai📍 Hangzhou Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Tests: FZ-AD005 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) NCT07327489n/a8 sites📍 Fort Smith📍 Frederick📍 Springfield Elephas · Tests: Biopsy A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors NCT06956690Phase 1, Phase 27 sites📍 La Jolla📍 Indianapolis📍 Farmington Hills Hummingbird Bioscience · Tests: ENV-501 BostonGene and Exigent Genomic INsight Study NCT06272864n/a7 sites📍 Rogers📍 Stockton📍 Fort Wayne BostonGene A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EBNK-001 + IL-15 + Pembrolizumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy